224
Participants
Start Date
August 31, 2006
Primary Completion Date
July 31, 2008
Study Completion Date
May 31, 2009
Ambrisentan
Oral tablets taken once daily.
St. Vincent's Hospital, Darlinghurst
Royal Perth Hospital, Perth
New York Presbyterian Pulmonary Hypertension Center, New York
Mary Parkes Asthma Center, Rochester
Allegheny General Hospital, Pittsburgh
University of Pittsburgh Medical Center Presbyterian, Pittsburgh
Johns Hopkins University, Baltimore
University of Virginia Health Sciences Center, Charlottesville
Duke University Medical Center, Durham
Lexington Pulmonary and Critical Care, Lexington
Atlanta Institute for Medical Research, Inc., Decatur
Medical College of Georgia, Augusta
Pulmonary Hypertension Clinic Mount Sinai Medical Center, Miami Beach
Suncoast Lung Center, Sarasota
University of Alabama at Birmingham, Birmingham
University Hospitals of Cleveland, Cleveland
The Lindner Clinical Trial Center, Cincinnati
University of Iowa Hospitals and Clinics, Iowa City
Mayo Clinic, Rochester
University of Chicago Hospitals, Chicago
Washington University School of Medicine, St Louis
Baylor College of Medicine, Houston
University of Colorado Health Sciences Center, Aurora
Arizona Pulmonary Specialists, Ltd, Phoenix
Greater Los Angeles, VA Medical Center, Los Angeles
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance
UCSD Medical Center, Thornton Hospital, La Jolla
Legacy Clinical Northwest, Portland
University of Connecticut Health Center, Farmington
Tufts-New England Medical Center, Boston
Massachusetts General Hospital, Boston
Boston Adult Congenital Heart Service, Boston
Boston University School of Medicine, Boston
University of Medicine & Dentistry of New Jersey, Newark
Newark Beth Israel Medical Center, Newark
Rhode Island Hospital, Providence
Peter Lougheed Centre, Calgary
University of Alberta Hospitals, Edmonton
Toronto General Hospital, Toronto
Lead Sponsor
Gilead Sciences
INDUSTRY